Basel, Switzerland, Sunday, April 21, 2024 – CIS BIOPHARMA, a leading oncology-focused biotech company, participated in the Swiss Biotech Day 2024, organized by the Swiss Biotech Association. The event, one of the largest gatherings in the global biotech community, brought together industry leaders, researchers, and investors to showcase the latest advancements in oncology, cardiovascular and other disease areas.

Christoph Schäfer, CEO of CIS BIOPHARMA, commented: «The Swiss Biotech Day provided an excellent platform to present our innovative antibody-drug conjugates and radioligand therapies. The level of engagement and interest in our pipeline was truly encouraging.“

Anders Harfstrand, member of CIS BIOPHARMA’s Board of Directors, added:  «This event underscored the resilience and innovative spirit of Switzerland’s biotech sector. Despite recent challenges, the industry is clearly on a path of recovery and growth.“

CIS BIOPHARMA’s participation in the Swiss Biotech Day 2024 reinforces its commitment to advancing cancer treatments and collaborating with leaders in the biotech community to improve patient outcomes.

About CIS BIOPHARMA AG

CIS BIOPHARMA is a privately owned, Basel-based oncology company that develops next-generation immuno-conjugates to address aggressive forms of tumors. The product pipeline includes antibody-drug conjugates, ADCs, and radioligand therapies, RLTs, selectively targeting tumor cells. CIS BIOPHARMA aims to help cancer patients live longer and better lives.